Polyomavirus Agnoprotein Detection in Body Fluids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting polyomavirus reactivation and active infection are unreliable due to persistent latent infections, lacking effective biomarkers for early diagnosis, particularly for progressive multifocal leukoencephalopathy (PML), which often results in late-stage diagnosis.
Innovation Solution
Detection of polyomavirus agnoprotein and/or agnoprotein antibodies in body fluids such as blood, urine, and cerebrospinal fluid, allowing for non-invasive monitoring of polyomavirus reactivation and active infection, with methods including antibody-based assays and enzyme-linked immunosorbent assays to assess the presence and levels of these markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If detection methods using polyomavirus DNA and/or anti-polyomavirus antibodies are employed, then diagnosis of polyomavirus reactivation can be attempted, but reliability is poor due to persistent life long latent infection
Solution Approach 1:
The patent extracts and focuses on a specific viral protein (agnoprotein) that is uniquely produced during active replication, separating the detection target from the general viral presence. This allows differentiation between latent infection (where agnoprotein is not produced) and active reactivation (where agnoprotein is produced and secreted), thereby resolving the reliability issue of general DNA/antibody detection methods.
Solution Approach 2:
The patent uses agnoprotein as an intermediary biomarker that mediates the detection of active viral replication. Instead of directly detecting viral DNA or antibodies which remain positive during latency, agnoprotein serves as an intermediate marker that is only present during active infection, providing reliable information about current viral status.
2Reliability
If tissue biopsy is used to detect agnoprotein in brain tissue, then diagnosis of PML can be made, but the method is invasive and associated with pain, risk of infection, hemorrhage, and damage to healthy tissue
Solution Approach 1:
The patent uses agnoprotein as an intermediary marker that can be detected in body fluids (blood, urine, CSF) rather than requiring direct tissue biopsy. This intermediary approach maintains diagnostic accuracy while eliminating the invasive nature of brain tissue biopsy, thereby resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent creates a non-invasive copy of the diagnostic information by detecting agnoprotein in body fluids that mirror the viral replication status in the brain. Instead of directly sampling the brain tissue (which is invasive), the method uses fluid samples as a copy that contains the same diagnostic information, thereby maintaining accuracy while avoiding procedure complications.
3Productivity
If detection of polyomavirus DNA and antibodies is performed, then monitoring of viral infection can be attempted, but the methods are not suitable for early diagnosis and routine screening
Solution Approach 1:
The patent extracts and utilizes agnoprotein, a protein specifically produced during active viral replication, as the detection target. This extraction allows for early detection of reactivation events before clinical symptoms manifest, enabling timely intervention and improving screening efficiency for immunocompromised patients.
Solution Approach 2:
The patent enables preliminary detection of viral reactivation by monitoring agnoprotein levels in body fluids before clinical disease manifestations occur. This preliminary action allows for early intervention and prevents progression to severe disease, thereby reducing time loss and improving screening productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and monitoring of polyomavirus reactivation and active infection, reducing the risk of developing associated diseases like PML, with less invasive and cost-effective methods compared to tissue biopsies, facilitating routine screening and risk assessment for immunocompromised patients.
Implementation Method 1
polyomavirus agnoprotein is secreted from cells having an active polyomavirus infection and can be detected in body fluids
Implementation Method 2
determining the presence or absence of a polyomavirus agnoprotein and/or the presence or absence of agnoprotein antibodies in the biological sample
Data Source
AI summary
The invention provides methods of detection and monitoring of polyomavirus reactivation and active polyomavirus infections using a biological fluid sample. Also provided are methods of risk assessment and risk monitoring of developing a polyomavirus-associated disease.